Diffuse Large B-Cell Lymphoma (dlbcl) Clinical Trials
2 recruiting trials for Diffuse Large B-Cell Lymphoma (dlbcl). Eligibility criteria explained in plain English.
TrialFinderData lists 2 Diffuse Large B-Cell Lymphoma (dlbcl) clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Across the trials that carry a phase, Phase 2 is the largest group at 50% (1 studies); the largest phase groups are Phase 2: 1, Phase 1: 1.
Research is led by Second Affiliated Hospital, School of Medicine, Zhejiang University (1), Nurix Therapeutics, Inc. (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is orelabrutinib combined with the Pola-R-CHP regimen (drug, 1 trial), followed by NX-1607, Paclitaxel.
Track Diffuse Large B-Cell Lymphoma (dlbcl) trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Orelabrutinib Combined With Pola-R-CHP Regimen for the Treatment of Untreated Non-GCB Diffuse Large B-Cell Lymphoma
Assess the preliminary efficacy and safety of orelabrutinib in combination with the Pola-R-CHP regimen for the treatment of treatment-naive Non-GCB diffuse large B-cell lymphoma.
A Study of NX-1607 in Adults With Advanced Malignancies
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced...
Explore Other Conditions
Frequently Asked Questions
There are currently 2 clinical trials for Diffuse Large B-Cell Lymphoma (dlbcl), with 2 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Diffuse Large B-Cell Lymphoma (dlbcl), review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Diffuse Large B-Cell Lymphoma (dlbcl), representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.